Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation.
Patients undergoing allogeneic bone marrow transplantation who are seropositive for cytomegalovirus are vulnerable to serious cytomegalovirus infection, presumably because of reactivation of latent endogenous virus and severe immunosuppression. We administered intravenous acyclovir from 5 days before to 30 days after allogeneic marrow transplantation for hematologic neoplasms in an effort to prevent cytomegalovirus infection and disease in patients seropositive for cytomegalovirus before transplantation. Eighty-six patients seropositive for both cytomegalovirus and herpes simplex virus before transplantation received acyclovir, whereas 65 patients seropositive only for cytomegalovirus served as controls (acyclovir is the standard prophylactic agent against herpes simplex virus in this setting). The probability that cytomegalovirus infection would develop within the first 100 days after transplantation was 0.70 among acyclovir recipients and 0.87 among control patients at medians of 62 and 40 days after transplantation, respectively (P = 0.0001 by log-rank test). Invasive cytomegalovirus disease developed in 19 acyclovir recipients (22 percent) and 25 control patients (38 percent) (P = 0.008). Survival within the first 100 days after transplantation was better among acyclovir recipients (P = 0.002). Acyclovir prophylaxis was associated with a relative risk of 0.5 or less for the development of cytomegalovirus infection or disease or for death within the first 100 days after transplantation (P less than or equal to 0.04), in proportional-hazards regression analysis. We conclude that prophylaxis with intravenous acyclovir significantly reduced the risk of both cytomegalovirus infection and cytomegalovirus disease in seropositive patients after allogeneic bone marrow transplantation and that it was also associated with significantly improved survival.
Meyers
J D
JD
Fred Hutchinson Cancer Research Center, Program in Infectious Diseases, Seattle, WA 98104.
Reed
E C
EC
Shepp
D H
DH
Thornquist
M
M
Dandliker
P S
PS
Vicary
C A
CA
Flournoy
N
N
Kirk
L E
LE
Kersey
J H
JH
Thomas
E D
ED
D000212:Acyclovir / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D000704:Analysis of Variance; D000914:Antibodies, Viral / Q000032:analysis; D016026:Bone Marrow Transplantation; D002648:Child; D002675:Child, Preschool; D003587:Cytomegalovirus / Q000276:immunology; D003586:Cytomegalovirus Infections / Q000517:prevention & control*; D004341:Drug Evaluation; D005260:Female; D006086:Graft vs Host Disease / Q000453:epidemiology; D006561:Herpes Simplex / Q000517:prevention & control; D006801:Humans; D007275:Injections, Intravenous; D007938:Leukemia / Q000628:therapy; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000517:prevention & control*; D011658:Pulmonary Fibrosis / Q000517:prevention & control; D012307:Risk Factors
D000914:Antibodies, Viral; D000212:Acyclovir